DEN250006 · Amferia AB · SHA · Feb 6, 2026 · General, Plastic Surgery
Device Facts
Record ID
DEN250006
Device Name
Amferia Wound Dressing
Applicant
Amferia AB
Product Code
SHA · General, Plastic Surgery
Decision Date
Feb 6, 2026
Decision
DENG
Submission Type
Direct
Regulation
21 CFR 878.4013
Device Class
Class 2
Attributes
Therapeutic
Indications for Use
Amferia Wound Dressing is intended to cover and protect dry-to-low exuding wounds (e.g. abrasions, skin tears, lacerations, incisions and surgical wounds, superficial and partial-thickness burns, pressure ulcers, arterial ulcers), and to maintain an appropriate moisture balance within the wound.
Device Story
Amferia Wound Dressing is a sterile, solid wound dressing featuring an antimicrobial agent permanently bound to the substrate surface. Designed for external cutaneous wounds, it functions as a physical barrier to protect the wound, absorb exudate, and maintain moisture balance. The antimicrobial component acts solely as a protectant to reduce microbial growth within the dressing or prevent microbial penetration through the dressing; it is not intended to affect wound bioburden. The device is applied by healthcare professionals in clinical settings. It does not contain medically important antimicrobials. Performance is supported by biocompatibility, leachability, and microbial barrier testing to ensure the antimicrobial remains bound to the substrate during use.
Clinical Evidence
No clinical data provided. Evidence consists of non-clinical performance testing, including biocompatibility evaluation, antimicrobial leachability testing, microbial barrier testing, and shelf life/sterilization validation to demonstrate safety and effectiveness.
Technological Characteristics
Solid wound dressing with permanently bound antimicrobial agent. Characteristics include substrate material, antimicrobial identity, and bonding mechanism (e.g., covalent or ionic). Must demonstrate sterility, biocompatibility, and non-leachability of the antimicrobial. Requires establishment of Minimum Effective Concentration (MEC) and shelf life validation. Does not contain medically important antimicrobials.
Indications for Use
Indicated for patients with dry-to-low exuding wounds including abrasions, skin tears, lacerations, incisions, surgical wounds, superficial and partial-thickness burns, pressure ulcers, and arterial ulcers. Contraindicated for patients with known sensitivity to components within the product.
Regulatory Classification
Identification
Amferia Wound Dressing is a solid wound dressing with a permanently bound antimicrobial agent. It is intended to cover and protect dry-to-low exuding wounds (e.g., abrasions, skin tears, lacerations, incisions and surgical wounds, superficial and partial-thickness burns, pressure ulcers, arterial ulcers) and to maintain an appropriate moisture balance within the wound. The device consists of a solid wound dressing containing an antimicrobial permanently bound to the substrate surface, used to cover and protect a wound, absorb exudate, and maintain moisture balance on external cutaneous (skin) wounds.
Special Controls
In combination with the general controls of the FD&C Act, the wound dressing with permanently bound antimicrobial agent is subject to the following special controls:
- (1) The device must not contain antimicrobials considered by FDA to be medically important. Medically important antimicrobials are antimicrobials that are important for therapeutic use in humans and associated with a high level of antimicrobial resistance concern (AMR). Medically important antimicrobials include the following classes: Allylamines, Aminocyclitols, Aminoglycosides, Aminomethylcyclines, Amphenicols, Antifolates, Ansamycins, Azoles, Betalactams both with and without Beta-lactamase inhibitors, Carbapenems, Cephalosporins, Cephamycins, Cyclic Polypeptides, Dihydrofolate Reductase Inhibitors, Echinocandins, Fluorocyclines, Fluoroquinolones, Fosfomycins, Fusidanes, Glycopeptides, Glycylcyclines, Heterocyclic compounds, Hydroquinolones, Lincosamides, Lipoglycopeptides, Lipopeptides, Macrolides and Ketolides, Macrocyclic peptides, Monobactams, Nitrofurans, Nitroimidazoles, Oxazolidinones, Penems, Penicillins, Phosphonic Acid Derivatives, Pleuromutilins, Polyenes, Polymyxins, Pseudomonic acids, Quinolones, Rifampin, Riminofenazines, Streptogramins, Sulfonamides, Sulfones, or Tetracyclines.
- (2) Performance testing and technological characteristics must demonstrate the functionality of the device to achieve the intended use, including:
- (i) The physical and chemical characteristics of the solid wound dressing must be established. The following must be provided:
- (A) Identity, quantification, and purpose of each component in the finished product;
- (B) Description of the process by which the antimicrobial is bound to the substrate, including the resulting type of bonding (e.g. covalent, ionic, etc.);
- (C) Specifications and characterization of each component in the finished product; and
- (D) Final release specifications for the manufactured solid wound dressing.
- (ii) Performance data must demonstrate that components are present in appropriate amounts to perform as intended under anticipated conditions of use, including evaluation of expected worst-case conditions.
- (iii) The device must be demonstrated to be sterile.
- (iv) The device must be demonstrated to be biocompatible.
- (v) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including evaluation of expected worst-case conditions.
- (vi) Performance data must support the shelf life of the device by demonstrating package integrity and product functionality over the identified shelf life.
- (3) Antimicrobial characterization and performance testing must address the following:
- (i) The technological characteristics of the device must indicate the purpose of the antimicrobial and performance data must demonstrate it is present in appropriate amounts to perform as intended under anticipated conditions of use and storage conditions. If the antimicrobial is present as a microbial barrier to cover and protect a wound, microbial barrier testing must demonstrate elimination of passage of microorganisms through the solid wound dressing. If the antimicrobial is present to inhibit microbial growth within the solid wound dressing being used to cover and protect a wound, antimicrobial effectiveness testing must demonstrate inhibition of microbial growth within the solid wound dressing during use. This testing must include:
- (A) Establishment of the Minimum Effective Concentration (MEC) of the antimicrobial in the context of the final solid wound dressing;
- (B) Identification of the period of effectiveness (i.e., maximum product use life) based on concentration of antimicrobial, leachability data, and performance under expected worst-case simulated use conditions; and
- (C) For the tests conducted, evaluation with clinically relevant microbial species, including available strains of challenge organisms containing specific antimicrobial resistance mechanisms as part of expected worst-case scenario performance testing.
- (ii) Performance test data must demonstrate that the antimicrobial is bound to the dressing substrate and does not leach from the dressing. This testing must include:
- (A) Extraction studies exposing the dressing to justified conditions to evaluate the leachability of the antimicrobial (e.g. prolonged extraction in solvents of different polarity at elevated temperatures); and
- (B) Assessment of the potential for substrate and/or coating degradation leading to leaching of the antimicrobial.
- (iii) Evaluation and identification, based on literature review, of any probable risks for probable contributions to the development and spread of antimicrobial resistance (AMR) must be provided, and must include:
- (A) Identification of the antimicrobial, proposed mechanism(s) of action, and expected spectrum of activity; and
- (B) An AMR assessment for each antimicrobial, including the following characterization elements based on literature review:
- (1) Known resistance mechanisms;
- (2) Transmissibility of resistance mechanisms;
- (3) List of resistant microbial species; and
- (4) Potential for coselection (e.g., via coresistance or cross-resistance) for medically important antimicrobial resistance mechanisms.
(4) Any statements in labeling must be clear such that they may be understood by the end user, supported by appropriate evidence, and consistent with the intended use of covering and protecting a wound, absorbing exudate, and maintaining appropriate moisture balance within the wound. The labeling must include:
- (i) Instructions regarding the proper placement, sizing, duration of use for the solid wound dressing, frequency of use, and removal of the solid wound dressing, if applicable;
- (ii) A list of each ingredient or component within the solid wound dressing;
- (iii) A warning statement regarding any known incompatibilities with other potential therapies;
- (iv) Instructions to monitor for signs of infection;
- (v) A statement regarding the potential retention of material in the wound or the surrounding area and any applicable instructions for removal of this material;
- (vi) A contraindication for any known sensitivity to components within the product;
- (vii) A shelf life (i.e., maximum period the unopened solid wound dressing is stable while stored on the shelf under a specified range of environmental conditions);
- (viii) A maximum use life per application of solid wound dressing (i.e., period the solid wound dressing is recommended for use prior to removal);
- (ix) A statement regarding when to discontinue use of the solid wound dressing after multiple reapplications based on biocompatibility and performance testing;
- (x) A statement of the role of the antimicrobial in the device. All statements regarding the antimicrobial must be consistent with and placed in the context of the role as a protectant;
- (xi) A warning statement regarding the potential for selection of antibiotic resistant organisms if the wound dressing contains an antimicrobial that may indirectly select for organisms with medically important antimicrobial resistance mechanisms; and
- (xii) A statement that the antimicrobial is not intended to affect wound bioburden.
Submission Summary (Full Text)
{1}
# DE NOVO CLASSIFICATION REQUEST FOR
AMFERIA WOUND DRESSING
## REGULATORY INFORMATION
FDA identifies this generic type of device as:
**Solid wound dressing with permanently bound antimicrobial agent.** A solid wound dressing with permanently bound antimicrobial agent consists of a solid wound dressing containing antimicrobial permanently bound to the substrate surface. The solid wound dressing is used to cover and protect a wound, to absorb exudate, and to maintain appropriate moisture balance within the wound and is intended for use only on external cutaneous (skin) wounds. The solid wound dressing is provided sterile in a form able to hold structural integrity. Antimicrobials are used for protectant purposes only to reduce microbial growth within the solid wound dressing while in use, or to provide an antimicrobial barrier to microbial penetration through the solid wound dressing. This classification does not include solid wound dressings containing a medically important antimicrobial as defined in special control (1).
**NEW REGULATION NUMBER:** 21 CFR 878.4013
**CLASSIFICATION:** Class II
**PRODUCT CODE:** SHA
## BACKGROUND
**DEVICE NAME:** Amferia Wound Dressing
**SUBMISSION NUMBER:** DEN250006
**DATE DE NOVO RECEIVED:** March 3, 2025
## SPONSOR INFORMATION:
Amferia AB
% AZ BioVentureHub Astra Zeneca
Pepparedsleden 1
Mölndal, SE, 43183, Sweden
## INDICATIONS FOR USE
The Amferia Wound Dressing is indicated as follows:
Amferia Wound Dressing is intended to cover and protect dry-to-low exuding wounds (e.g. abrasions, skin tears, lacerations, incisions and surgical wounds, superficial and
{2}
partial-thickness burns, pressure ulcers, arterial ulcers), and to maintain an appropriate moisture balance within the wound.
# LIMITATIONS
The sale, distribution, and use of the Amferia Wound Dressing are restricted to prescription use in accordance with 21 CFR 801.109.
PLEASE REFER TO THE LABELING FOR A COMPLETE LIST OF WARNINGS, PRECAUTIONS AND CONTRAINDICATIONS.
# DEVICE DESCRIPTION
Amferia Wound Dressing is an occlusive, sterile, single use, solid sheet dressing. The solid sheet dressing is surface-modified with a permanently bound antibacterial peptide.
Amferia Wound Dressing is intended to act as a physical barrier to outside contaminants and is not intended to act on the surface or interior of the wound. The antibacterial surface modification only inhibits or minimizes bacterial growth on or within the dressing itself.
The solid wound dressing is made of permanently crosslinked Poloxamer 407, glycerol, and water and is surface modified with a permanently bound antibacterial peptide with the R(RP)4W4 sequence. The amount of the permanently bound antibacterial peptide present is 5.4 micrograms/cm².
# SUMMARY OF NONCLINICAL/BENCH STUDIES
# BIOCOMPATIBILITY/MATERIALS
The Amferia Wound Dressing is categorized as a device in prolonged (>24 h to 30 d) contact with breached or compromised surfaces. The sponsor has addressed the following biocompatibility endpoints according to the relevant FDA guidance and standards:
- Cytotoxicity - MTS Cytotoxicity Test (ISO 10993-5)
- Sensitization - Guinea Pig Maximization Test (ISO 10993-10)
- Irritation - Intracutaneous Reactivity (ISO 10993-23)
- Acute Systemic Toxicity (ISO 10993-11)
- Material-mediated pyrogenicity - Rabbit Pyrogen Test (USP \(< 151>\), ISO 10993-11)
- Subacute/subchronic systemic toxicity - Analytical chemical characterization and Toxicological risk assessment (ISO 10993-17, ISO 10993-18)
- Implantation - Porcine wound healing study (ISO 10993-6)
The results demonstrate that the Amferia Wound Dressing is biocompatible.
# SHELF LIFE/STERILITY
De Novo Summary (DEN250006)
Page 2 of 9
{3}
The Amferia Wound Dressing is sterilized via e-beam irradiation in accordance with ISO 11137-2 to a sterility assurance level (SAL) of 10⁻⁶. The shelf life was verified to be 18 months based on real time aging.
## PERFORMANCE TESTING - BENCH
Moisture Vapour Transmission Rate and Free Swell Absorptive Capacity testing were performed to evaluate moisture permeability and absorptive performance of the Amferia wound dressing. The testing was based on EN 13726. Test results demonstrate that the subject device can maintain an appropriate moisture balance.
Non-leachability testing was performed to demonstrate that the antibacterial peptide is covalently attached to the solid wound dressing surface and does not leach from the dressing. Testing performed included:
- Zone of inhibition
- Microbiology testing after in vitro extraction
- Comparison of covalently bound vs physically absorbed peptide
- Exhaustive solvent extraction
- Targeted chemical analysis
There was no evidence of antibacterial peptide leaching from the Amferia wound dressing based on the results of the testing.
Minimum effective concentration (MEC) testing was performed to determine the minimum effective concentration of the antibacterial peptide required to support the intended use. The results demonstrated that the MEC is 5.4 µg/cm².
Antibacterial effectiveness testing was performed to characterize the performance of the Amferia wound dressing. The test method was based on AATCC 100, JIS Z 2801, and ISO 22196. Test results demonstrate a >4 log reduction against three gram-positive and three gram-negative bacterial species. The testing included modifications of the aforementioned standards – including conditioning the test article - to represent the clinical use of the product.
Bacterial barrier testing was performed to demonstrate prevention of the penetration of bacteria, including motile species, through the subject device. The test method was a modified version of the ASTM E3383 standard. Barrier effectiveness was evaluated, comparing the Amferia wound dressing to a control - unmodified material with no antibacterial peptide. Test results demonstrate that the Amferia Wound Dressing is an effective barrier against the penetration of three gram-positive and three gram-negative bacterial species, including motile species.
A wearability study was conducted by applying the Amferia Wound Dressing on intact skin of healthy volunteers with different secondary dressings for 72 hours. Photos were taken of the subject device at the beginning and end of the application period. Moisture retention and device stretch were evaluated at the end of the application period. Test results demonstrate that the Amferia wound dressing did not lose adherence or become excessively dehydrated over the 3-day study period though the moisture retention varied depending upon the secondary dressing
De Novo Summary (DEN250006)
Page 3 of 9
{4}
that was used. When using the recommended secondary dressing, dehydration percentage of the subject device was limited to 29.55-40.00% after 72 hours.
AMR risk was assessed for the Amferia wound dressing using a literature review approach. The antibacterial peptide is not a medically important antimicrobial and is not associated with a high level of AMR concern.
## LABELING
The Amferia Wound Dressing labeling meets the requirements of 21 CFR 801.109 for prescription devices. It contains the indications for use, prescription only symbol, device description, contraindications, general warnings and precautions, instructions for use including disposal instructions, potential adverse events, storage conditions, and symbols and markings. Furthermore, the packaging includes a shelf life for the device.
The labeling also meets the requirements of the special controls set forth for this device type. It contains:
- • Instructions regarding the proper placement, sizing, duration of use for the solid wound dressing, frequency of use, and removal of the solid wound dressing;
- • A list of each ingredient or component within the solid wound dressing;
- • Instructions to monitor for signs of infection;
- • A statement regarding the potential retention of material in the wound or the surrounding area and instructions to remove this material, if observed;
- • A contraindication for any known sensitivity to components within the product;
- • A shelf life (i.e., maximum period the unopened solid wound dressing is stable while stored on the shelf under a specified range of environmental conditions);
- • A maximum use life per application of solid wound dressing (i.e., period the solid wound dressing is recommended for use prior to removal);
- • A statement regarding when to discontinue use of the solid wound dressing after multiple reapplications based on biocompatibility and performance testing;
- • A statement of the role of the antibacterial in the product. All statements regarding the antibacterial are consistent with and placed in the context of the role as a protectant;
- • A statement explaining that the antibacterial is not intended to affect wound bioburden.
## RISKS TO HEALTH
The table below identifies the risks to health that may be associated with use of a wound dressing with permanently bound antimicrobial agent and the measures necessary to mitigate these risks.
| Risks to Health | Mitigation Measures |
| --- | --- |
| Adverse tissue reaction | Performance testing and technological characteristics Biocompatibility evaluation Antimicrobial leachability testing Labeling |
| Toxicity | Performance testing and technological characteristics Biocompatibility evaluation |
*De Novo Summary (DEN250006)*
Page 4 of 9
{5}
| | Antimicrobial leachability testing Labeling |
| --- | --- |
| Delayed wound healing | Performance testing and technological characteristics Biocompatibility evaluation Antimicrobial leachability testing Labeling |
| Incompatibilities with other therapies | Labeling |
| Contribution to the spread of antimicrobial resistance (AMR) | Exclusion of medically important antimicrobials Antimicrobial characterization and performance testing Antimicrobial leachability testing AMR risk assessment Labeling |
| Infection | Antimicrobial characterization and performance testing Shelf life validation Sterilization validation Labeling |
| Microbial growth within the product during use | Antimicrobial characterization and performance testing Antimicrobial leachability testing Sterilization validation |
| Product degradation during stated shelf storage | Shelf life validation Labeling |
| Retention of dressing material in wound | Performance testing and technological characteristics Labeling |
| Loss of barrier function | Antimicrobial characterization and performance testing |
## SPECIAL CONTROLS
In combination with the general controls of the FD&C Act, the wound dressing with permanently bound antimicrobial agent is subject to the following special controls:
(1) The device must not contain antimicrobials considered by FDA to be medically important. Medically important antimicrobials are antimicrobials that are important for therapeutic use in humans and associated with a high level of antimicrobial resistance concern (AMR). Medically important antimicrobials include the following classes: Allylamines, Aminocyclitols, Aminoglycosides, Aminomethylcyclines, Amphenicols, Antifolates, Ansamycins, Azoles, Beta-lactams both with and without Beta-lactamase inhibitors, Carbapenems, Cephalosporins, Cephamycins, Cyclic Polypeptides, Dihydrofolate Reductase Inhibitors, Echinocandins, Fluorocyclines, Fluoroquinolones, Fosfomycins, Fusidanes, Glycopeptides, Glycylcyclines, Heterocyclic compounds, Hydroquinolones, Lincosamides, Lipoglycopeptides, Lipopeptides, Macrolides and Ketolides, Macrocyclic peptides, Monobactams, Nitrofurans, Nitroimidazoles, Oxazolidinones, Penems, Penicillins, Phosphonic Acid Derivatives, Pleuromutilins,
De Novo Summary (DEN250006)
Page 5 of 9
{6}
Polyenes, Polymyxins, Pseudomonic acids, Quinolones, Rifampin, Riminofenazines, Streptogramins, Sulfonamides, Sulfones, or Tetracyclines.
(2) Performance testing and technological characteristics must demonstrate the functionality of the device to achieve the intended use, including:
(i) The physical and chemical characteristics of the solid wound dressing must be established. The following must be provided:
(A) Identity, quantification, and purpose of each component in the finished product;
(B) Description of the process by which the antimicrobial is bound to the substrate, including the resulting type of bonding (e.g. covalent, ionic, etc.);
(C) Specifications and characterization of each component in the finished product; and
(D) Final release specifications for the manufactured solid wound dressing.
(ii) Performance data must demonstrate that components are present in appropriate amounts to perform as intended under anticipated conditions of use, including evaluation of expected worst-case conditions.
(iii) The device must be demonstrated to be sterile.
(iv) The device must be demonstrated to be biocompatible.
(v) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including evaluation of expected worst-case conditions.
(vi) Performance data must support the shelf life of the device by demonstrating package integrity and product functionality over the identified shelf life.
(3) Antimicrobial characterization and performance testing must address the following:
(i) The technological characteristics of the device must indicate the purpose of the antimicrobial and performance data must demonstrate it is present in appropriate amounts to perform as intended under anticipated conditions of use and storage conditions. If the antimicrobial is present as a microbial barrier to cover and protect a wound, microbial barrier testing must demonstrate elimination of passage of microorganisms through the solid wound dressing. If the antimicrobial is present to inhibit microbial growth within the solid wound dressing being used to cover and protect a wound, antimicrobial effectiveness testing must demonstrate inhibition of microbial growth within the solid wound dressing during use. This testing must include:
(A) Establishment of the Minimum Effective Concentration (MEC) of the antimicrobial in the context of the final solid wound dressing;
(B) Identification of the period of effectiveness (i.e., maximum product use life) based on concentration of antimicrobial, leachability data, and performance under expected worst-case simulated use conditions; and
(C) For the tests conducted, evaluation with clinically relevant microbial species, including available strains of challenge organisms containing specific antimicrobial resistance mechanisms as part of expected worst-case scenario performance testing.
De Novo Summary (DEN250006)
Page 6 of 9
{7}
- (ii) Performance test data must demonstrate that the antimicrobial is bound to the dressing substrate and does not leach from the dressing. This testing must include:
- (A) Extraction studies exposing the dressing to justified conditions to evaluate the leachability of the antimicrobial (e.g. prolonged extraction in solvents of different polarity at elevated temperatures); and
- (B) Assessment of the potential for substrate and/or coating degradation leading to leaching of the antimicrobial.
- (iii) Evaluation and identification, based on literature review, of any probable risks for probable contributions to the development and spread of antimicrobial resistance (AMR) must be provided, and must include:
- (A) Identification of the antimicrobial, proposed mechanism(s) of action, and expected spectrum of activity; and
- (B) An AMR assessment for each antimicrobial, including the following characterization elements based on literature review:
- (1) Known resistance mechanisms;
- (2) Transmissibility of resistance mechanisms;
- (3) List of resistant microbial species; and
- (4) Potential for coselection (e.g., via coresistance or cross-resistance) for medically important antimicrobial resistance mechanisms.
- (4) Any statements in the labeling must be clear such that they may be understood by the end user, supported by appropriate evidence, and consistent with the intended use of covering and protecting a wound, absorbing exudate, and maintaining appropriate moisture balance within the wound. The labeling must include:
- (i) Instructions regarding the proper placement, sizing, duration of use for the solid wound dressing, frequency of use, and removal of the solid wound dressing, if applicable;
- (ii) A list of each ingredient or component within the solid wound dressing;
- (iii) A warning statement regarding any known incompatibilities with other potential therapies;
- (iv) Instructions to monitor for signs of infection;
- (v) A statement regarding the potential retention of material in the wound or the surrounding area and any applicable instructions for removal of this material;
- (vi) A contraindication for any known sensitivity to components within the product;
- (vii) A shelf life (i.e., maximum period the unopened solid wound dressing is stable while stored on the shelf under a specified range of environmental conditions);
- (viii) A maximum use life per application of solid wound dressing (i.e., period the solid wound dressing is recommended for use prior to removal);
- (ix) A statement regarding when to discontinue use of the solid wound dressing after multiple reapplications based on biocompatibility and performance testing;
- (x) A statement of the role of the antimicrobial in the device. All statements regarding the antimicrobial must be consistent with and placed in the context of the role as a protectant;
- (xi) A warning statement regarding the potential for selection of antibiotic resistant organisms if the wound dressing contains an antimicrobial that may indirectly
*De Novo Summary (DEN250006)*
Page 7 of 9
{8}
select for organisms with medically important antimicrobial resistance mechanisms; and
(xii) A statement that the antimicrobial is not intended to affect wound bioburden.
## BENEFIT-RISK DETERMINATION
Amferia Wound Dressing is intended to cover and protect dry-to-low exuding wounds (e.g. abrasions, skin tears, lacerations, incisions and surgical wounds, superficial and partial-thickness burns, pressure ulcers, arterial ulcers), and to maintain an appropriate moisture balance within the wound.
The risks of the device are based on nonclinical laboratory and animal studies as well as information about the many solid wound dressing devices available on the market in the United States.
Probable risks associated with use of this device include adverse tissue reaction, toxicity, delayed wound healing, incompatibility with other therapies, contribution to the spread of antimicrobial resistance, infection, microbial growth within the product during use, product degradation during stated shelf life storage, retention of dressing material in wound, and loss of barrier function.
Clinical safety and performance data are not available for the subject device. These risks are informed in part by probable risks established for other solid wound dressing devices. The probable risks for other solid wound dressing devices were established through premarket submission reviews, FDA Advisory Committee meetings, review of adverse event reports, review of past recalls, and review of scientific literature. The proposed special controls are intended to mitigate these probable risks to health, and these special controls have been met for the subject device, Amferia Wound Dressing.
The probable benefits of the device are also based on nonclinical laboratory and animal studies as well as information about the many solid wound dressing devices available on the market in the United States.
Probable benefits associated with use of this device include covering and protecting a wound, absorbing exudate, and maintaining appropriate moisture balance within the wound. To protect means to provide a physical barrier to the external environment. The probable benefits of the antibacterial peptide include reducing bacterial growth within the solid wound dressing while in use or providing a barrier to bacterial penetration through the solid wound dressing.
As noted above, clinical safety and performance data are not available for the subject device. These benefits are informed in part by probable benefits established for other solid wound dressing devices. The probable benefits for other solid wound dressing devices were established through premarket submission reviews, FDA Advisory Committee meetings, review of clinical guidelines, and review of scientific literature. It has also been noted that the availability of a variety of wound dressings to support different approaches to care for the many types of wounds with heterogeneous wound bed characteristics can provide clinical benefit.
De Novo Summary (DEN250006)
Page 8 of 9
{9}
# PATIENT PERSPECTIVES
This submission did not include specific information on patient perspectives for this device.
# BENEFIT/RISK CONCLUSION
In conclusion, given the available information above, for the following indication statement:
Amferia Wound Dressing is intended to cover and protect dry-to-low exuding wounds (e.g. abrasions, skin tears, lacerations, incisions and surgical wounds, superficial and partial-thickness burns, pressure ulcers, arterial ulcers), and to maintain an appropriate moisture balance within the wound.
The probable benefits outweigh the probable risks for the Amferia Wound Dressing. The device provides benefits and the risks can be mitigated by the use of general and the identified special controls.
# CONCLUSION
The De Novo request for the Amferia Wound Dressing is granted and the device is classified as follows:
Product Code: SHA
Device Type: Solid wound dressing with permanently bound antimicrobial agent
Regulation Number: 21 CFR 878.4013
Class: Class II
De Novo Summary (DEN250006)
Page 9 of 9
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Guidance alerts
New and changed FDA guidance documents, emailed as a daily digest.
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.
Copy this now. It will not be shown again.
Connected apps
Apps you authorized through browser sign-in. Disconnecting revokes their access immediately.
Learn the FDA Browser
Two short videos show you everything — or skip straight to the written tutorial if you'd rather read. You can reopen this any time from the ? button in the top bar.
Part 1 — Search, results, and everyday workflows 16 min
Part 2 — Embeddings: the galaxy map 3 min
1. Search: exact and fuzzy
Type a phrase like "coronary artery calcification" into the search box. You get two kinds of results. Exact results match the literal phrase — prefix searches work ("coronary artery calcificati") but suffix searches do not. Fuzzy results match on the meaning and intent of your phrase rather than the exact words, and are sorted by relevance score. Hover over the Exact or Fuzzy badge on any row to see exactly why it matched.
Use the checkboxes above the results to narrow: SaMD keeps only Software as a Medical Device, AI / ML keeps only devices with AI.
Exact vs. fuzzy search: what's the difference?
Exact matches on the literal phrase (prefix search works, suffix does not). Fuzzy matches on the meaning and intent of the phrase rather than the exact words. Hover over the badge on any row to see why it matched.
You search "coronary artery calcification" and want only software devices with AI. What two filters do you apply?
Narrow by SaMD (Software as a Medical Device), then narrow by AI/ML (devices with AI).
2. The results table
Scroll right in the results table. The intended use is extracted for you — no need to open the PDF. The device story gives a high-level snapshot of what the device does and how it's used. The AI Performance sub-table shows each output name, acceptance criteria, observed values, and development/test dataset descriptions — the same format Innolitics uses for regulatory strategy outputs, and the fastest high-level fingerprint of an AI device. It is AI-generated but has been very reliable in practice.
Where do you find a device's intended use without opening the PDF?
Scroll right in the search results table. The intended use column is extracted for you; no need to dig into the 510(k) summary PDF.
What does the AI Performance sub-table show, and why is it useful?
Output name, acceptance criteria, observed values, development dataset description, and test dataset description. It's the same format we use for regulatory strategy output and Fast 510(k) input, and the fastest high-level fingerprint of an AI device. AI-generated but reliable in practice.
3. Judging fuzzy relevance
Fuzzy results trail off in relevance as you scroll. Use three signals to decide how far down to go: the fuzzy badge explanations, the intended use column, and whether your target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, you're past the relevant zone. A top hit with a low score (~0.4) and a stretched explanation is a hint the closest predicates are far away — the project may be headed for De Novo. Note the fuzzy search is a pattern match: it doesn't handle negation ("not") well, and hardware devices can appear — filter by SaMD/AI ML to cut them.
How do you judge how far down fuzzy search results to go?
Use the relevancy signals: the fuzzy badge explanations, the intended use column, and whether the target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, results are trailing off in relevancy.
4. Device detail page: chat and citations
Click a device name to open its detail page: device facts on the left, a chat window on the right. Ask something like "Describe the training data". The answer carries little citation bubbles — click one to jump to the highlighted passage in the source PDF, so you can verify every AI answer against the document. There's also a Download PDF button for sharing.
How do you verify an AI chat answer on the device detail page?
Click the citation bubbles to jump to the relevant highlight in the source document.
Reading rule for every project: how many summaries do you read in full?
At least the three most relevant 510(k) or De Novo summaries, in full. After that, use targeted chat questions to confirm your memory quickly. The tool supports this professional habit — it doesn't replace it.
5. Side-by-side comparison
Select multiple rows in the results table (aim for under ~10), then open the PDF Viewer tab. Ask one question — it goes to all selected devices in parallel, each with citations. This is the fastest way to compare and contrast devices: training data, PCCP scope, how they handled adding new scanners, and so on.
What does the side-by-side PDF viewer mode do?
Select multiple devices, open the PDF viewer tab, and ask one question (e.g., "Describe the training data"). It queries all selected devices simultaneously with citations, so you can compare and contrast quickly.
6. Collections
With rows selected, go to the Collections tab and create a labeled collection (e.g., "Cobb Angle Project"). Reload that selection any time — before a client call, pull up the collection and ask questions across all of its devices at once.
How do you save a set of selected devices for later use?
Select the rows, go to the Collections tab, and create a labeled collection (e.g., "Cobb Angle Project"). You can reload the selection anytime and carry it into the PDF viewer and other tabs that support selections.
7. Product codes and the regulations tree
Click a product code in the results to jump to it in the regulations tree — identification text, sibling product codes, and devices you can open in a PDF viewer on the right. Click a regulation number to see its identification, special controls, and related product codes. You can also search by product code or regulation number at the top of the tree. Always read the special controls if any exist for your device — it broadens your search and sharpens pre-kickoff research.
What can you do from the regulations tree view?
Browse product codes and regulation numbers, read the identification text and special controls, browse sibling product codes, open device PDFs on the right, and search by product code or regulation number at the top of the tree.
8. Chart view
Click Show Chart and segment by regulation number (or product code) to see which regulations dominate your result set. Clicking a regulation takes you into the regulations tree. Great for spotting that most matches are, say, hardware laparoscopic devices — a cue to go back and filter.
How do you see which regulations dominate a search result set?
Click "Show Chart" and segment by Regulation Number. Clicking a regulation takes you to the regulations tree.
9. The predicate graph
Open the Predicates tab for a family-tree view of predicate relationships. Click a node to trace its parents and children; selections from search carry over pre-selected. Commonly predicated devices are worth reading — a lot of people predicated them for a reason. The visual lineage is also handy on client calls, e.g. to show how a predicate family evolved and justify why your predicate still holds.
In the predicate graph, why are commonly predicated devices worth reading?
A lot of people predicated them for a reason. Clicking a node traces parents and children, and selections from search carry over pre-selected.
10. Embeddings: the galaxy map
The Embeddings tab plots every matching document in a 2-D "galaxy map" where semantically similar devices cluster together. Hover or click clusters to explore, and let AI label the clusters for you. Embeddings beat product codes for grouping: two devices can carry different product codes (LLZ vs. QIH) yet do the same thing — the embedding captures the meaning of the intended use and device story. This is also exactly how retrieval-augmented generation (RAG) works under the hood, and it makes a great visual on client calls.
Try it yourself
Head to the search page and work through a few of these AI/ML fuzzy searches to build intuition: perivascular fat on CT · aortic valve calcification opportunistic screening on noncontrast CT · breast cancer prediction on digital pathology slides · autism detection · gestational age prediction · a hearing aid that can also detect a pulse · foundation model based analysis of ECG · large language models · penetration test. Watch how the relevance scores, intended use, and AI Performance tables tell you when results stop being meaningful.